2023 World Conference on Lung Cancer (Posters)-EP12.01. The Safety and Efficacy of Aumolertinib in Advanced NSCLC Patients with EGFRm Who were Intolerant to Osimertinib: A Retrospective Clinical Study

EP12.01. The Safety and Efficacy of Aumolertinib in Advanced NSCLC Patients with EGFRm Who were Intolerant to Osimertinib: A Retrospective Clinical Study - PDF(Slides)

Back to course

Pdf Summary

A retrospective clinical study was conducted to evaluate the safety and efficacy of aumolertinib in advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations who were intolerant to osimertinib. The study collected data from 23 NSCLC patients with EGFR mutations from 13 hospitals in Jiangxi Province, China. The patients had previously received osimertinib but had to switch to aumolertinib due to adverse events (AEs) caused by osimertinib. The primary endpoint of the study was safety, and the secondary endpoint was progression-free survival (PFS). <br /><br />Results showed that all patients experienced AEs from osimertinib treatment, with 52.2% of patients reporting AEs of grade 3 or higher. The most common AEs included rash, diarrhea, oral ulcers, interstitial pneumonia, and abnormal blood test results. After switching to aumolertinib, the duration of treatment was more than three months, and no recurrence of AEs was observed in 21 patients. Additionally, two patients saw an improvement in their AEs from grade 3 to grade 1. The median PFS of aumolertinib was not reached, indicating a positive treatment response.<br /><br />The study suggests that switching to aumolertinib after recovering from AEs caused by osimertinib is a feasible and effective treatment regimen for NSCLC patients with EGFR mutations. This regimen offers good efficacy and a reduced risk of adverse events, which can improve the quality of life for patients with lung cancer. <br /><br />The findings highlight the importance of considering alternative treatment options in patients who cannot tolerate certain therapies. The study was conducted in a real-world setting, involving multiple hospitals, which increases the generalizability of the results. The researchers express gratitude to the patients, their families, and the healthcare professionals involved in the study.

Asset Subtitle

Longhua Sun

Meta Tag

Speaker Longhua Sun

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

retrospective clinical study

aumolertinib

NSCLC patients

EGFR mutations

adverse events

progression-free survival

treatment duration

positive treatment response

alternative treatment options

real-world setting